OPEN SOURCE PHARMA FOUNDATION
  • Home
  • About
    • History
    • Meet our team
    • Funders
    • OSPF-India >
      • Reports
  • Partners
  • Press
  • Achievements
  • Projects
    • All Projects
    • Publications
  • Ideas
    • COVID-19 Ideas
    • Other Ideas
  • Resources
  • Why We Need OSP
  • COVID-19 Response
    • Open Source COVID-19 Vaccine
    • Open Source COVID-19 Drugs: ​In Silico Drug Repurposing
    • OSP Idea Factory: C-19 Drug Discovery Hypotheses
    • Global Repurposing Platform COVID-19
    • Open Source COVID-19 Resources
  • Education
  • Events
  • Join
    • Volunteer
    • Contact us
  • Donate

Phase 2b Clinical Trials

In partnership with the National Institute for Research in Tuberculosis (NIRT), we have commenced a multicentric phase 2b clinical trial.

​According to the Tufts Center for the Study of Drug Development, the estimated average cost to develop and gain market approval for a new drug is approximately $2.6 billion USD. This includes out-of-pocket costs, which total approximately $1.4 billion, as well as opportunity costs of nearly $1.2 billion. The typical time for development ranges from 10-16 years.

At roughly less than 1% the cost and a decade faster than a big pharma model, we have commenced a phase 2B, open label, parallel arm, randomized controlled clinical trial among newly diagnosed sputum smear positive pulmonary TB patients to evaluate the anti-bacterial activity of Metformin.

There are several open elements to this clinical trial:
  1. The trial, as required, has been registered prospectively on the Government of India’s clinical trials site, www.ctri.nic.in, CTRI No. 011176, with the protocol available here.
  2. A peer-reviewed article concerning the trial and its protocol has been published in the British Medical Journal, and is available, open access, here .
  3. Data from this trial, after being fully assembled and anonymized, will be made open and publicly available, enabling advanced computational and other analyses.
  4. Critically, all intellectual property stemming from this trial will be placed in the public domain.
Learn more about the trials
Back to homepage
Picture
Picture
OSPF is a supporter of the Open Source Pharma Movement and Community
Our Locations:
OSPF NIAS Drug Discovery Lab
National Institute of Advanced Studies
Indian Institute of Science Campus
Main Block, F-24
Bangalore, KA 560012
​INDIA

OSPF-Paris
Centre de Recherches Interdiciplinaires
8bis Rue Charles V
Paris, 75004
FRANCE

OSPF-USA
188 Grand Street #236
New York, NY 10013
USA
​Registered Office:
Open Source Pharma Foundation
Manyata Tech Park
MFAR Green Heart Building, Level 7
Hebbal, Outer Ring Road
Bangalore, KA 560045 
INDIA 
​
OSPF-India

Contact:
+91 80 22185052 / +91 9880193120
​info@ospfound.org
Make a donation
  • Home
  • About
    • History
    • Meet our team
    • Funders
    • OSPF-India >
      • Reports
  • Partners
  • Press
  • Achievements
  • Projects
    • All Projects
    • Publications
  • Ideas
    • COVID-19 Ideas
    • Other Ideas
  • Resources
  • Why We Need OSP
  • COVID-19 Response
    • Open Source COVID-19 Vaccine
    • Open Source COVID-19 Drugs: ​In Silico Drug Repurposing
    • OSP Idea Factory: C-19 Drug Discovery Hypotheses
    • Global Repurposing Platform COVID-19
    • Open Source COVID-19 Resources
  • Education
  • Events
  • Join
    • Volunteer
    • Contact us
  • Donate